PSA Levels Chart by Age: Normal Ranges and Test Guide

Author: Ian C. Langtree - View Credentials
Published: 14 Feb 2015 - Updated: 1 Nov 2026
Publication Type: Charts, Graphs, Tables

Table of Contents:
Synopsis - Definition - Overview - FAQs - Insights, Updates - Related Content

Synopsis

This information explains the prostate-specific antigen (PSA) blood test, what PSA levels mean at different ages and why there is no single normal number for every man. It sets out the age-specific reference ranges from a community-based study of healthy men published in JAMA, which run from 0.0 to 2.5 ng/mL in men in their 40s up to 0.0 to 6.5 ng/mL in men in their 70s, and it explains why prostate growth, infection, BPH and some medicines can push results up without cancer being present. The page also compares current screening advice from the U.S. Preventive Services Task Force and the American Urological Association, including earlier testing for Black men and those with a strong family history or inherited gene mutations. Drawing on the National Cancer Institute, MedlinePlus and current urology guidelines, it gives men, seniors, people with disabilities and caregivers a clear, reliable basis for talking with a doctor about whether PSA testing is right for them.

At a Glance

• 1 - Only about 25 percent of men who have a biopsy because of a raised PSA are found to have prostate cancer.
• 2 - Men are advised to avoid sex or masturbation for 24 hours before a PSA test, because releasing semen can temporarily raise the result.
• 3 - Medicare covers an annual PSA test for eligible men over age 50, which can make regular testing easier for seniors and people with disabilities.
• 4 - About 13.2 percent of American men will be diagnosed with prostate cancer during their lifetime, and an estimated 333,830 new cases are expected in 2026.

Topic Definition

Prostate-Specific Antigen (PSA)

Prostate-specific antigen (PSA) is a protein produced by both normal and cancerous cells of the prostate gland, a small gland below the bladder that makes the fluid part of semen. Most PSA ends up in semen, but small amounts enter the bloodstream, where they can be measured with a simple blood test reported in nanograms per milliliter (ng/mL). PSA levels tend to rise with age and prostate size and can also go up because of benign prostatic hyperplasia, prostatitis, infection, recent ejaculation or certain medicines. A raised PSA is not a diagnosis of prostate cancer, but it is used as a screening marker to help decide who may need further tests such as an MRI or biopsy, and as a way to monitor men after prostate cancer treatment.

Overview

The prostate is a walnut-sized gland in the male reproductive system. It sits just below the bladder and in front of the rectum, and it makes the fluid part of semen [National Library of Medicine, 2025]. The urethra, the tube that carries urine and semen out of the body, runs through the center of the prostate. Because of its position, the back of the gland can be felt by a doctor during a rectal exam.

Prostate-specific antigen (PSA) is a protein made by both normal and cancerous cells of the prostate gland [National Cancer Institute, 2025]. PSA is mostly found in semen, but it is normal for small amounts to circulate in the blood of healthy men.

A PSA test measures the amount of PSA in the blood. A raised PSA level may point to prostate cancer, but it can also be caused by noncancerous conditions such as prostatitis (inflammation of the prostate), an enlarged prostate (benign prostatic hyperplasia, or BPH), a urinary tract infection or certain medicines [National Library of Medicine, 2025].

Prostate Cancer by the Numbers

Prostate cancer is one of the most common cancers in American men. The National Cancer Institute's SEER program estimates 333,830 new cases and 36,320 deaths in the United States in 2026, making up 15.8 percent of all new cancer cases. About 13.2 percent of men will be diagnosed with prostate cancer at some point in their lives, and the five-year relative survival rate is 98.2 percent [National Cancer Institute, 2026].

How a PSA Test Is Done

The PSA test is a simple blood test, often offered during regular doctor checkups. A health care professional takes a small sample of blood from a vein in the arm, which usually takes less than five minutes [National Library of Medicine, 2025]. Results are reported in nanograms of PSA per milliliter of blood (ng/mL) [National Cancer Institute, 2025].

Preparing for the Test

Some everyday activities can raise PSA for a short time. MedlinePlus advises avoiding sex or masturbation for 24 hours before the test [National Library of Medicine, 2025]. The National Cancer Institute notes that ejaculation, vigorous exercise such as cycling, a prostate infection or a recent prostate biopsy can all push levels up, and that men are generally advised to avoid ejaculation and strenuous exercise for 2 days before testing [National Cancer Institute, 2025]. Tell the doctor about every medicine being taken, but do not stop any medicine without medical advice.

Men with mobility impairments can usually have blood drawn while seated in their own wheelchair. If a rectal exam is also planned, it is reasonable to ask ahead of time whether the clinic has a height-adjustable exam table, and a caregiver or support person can attend the appointment if that helps.

What Is a Normal PSA Level?

There is no single PSA level that is normal for every man. In general, the higher the PSA, the more likely prostate cancer is present, but it is possible to have a high PSA without cancer or a low PSA with cancer [National Library of Medicine, 2025]. A level above 4.0 ng/mL has generally been considered abnormal and may lead to further testing. Some doctors use a lower cutoff of about 2.5 ng/mL for younger men and a higher cutoff of about 5 ng/mL for older men. A lower cutoff is also used for men taking finasteride or dutasteride, drugs that lower PSA [National Cancer Institute, 2025].

Because the prostate tends to grow with age and produce more PSA, PSA levels normally rise as men get older. A community-based study of 471 healthy men aged 40 to 79 with no sign of prostate cancer, published in JAMA, found that PSA was linked to both age and prostate size and rose by about 3.2 percent a year in a healthy 60-year-old man. The researchers used these results to set age-specific reference ranges [Oesterling et al., 1993].

PSA Levels Chart by Age

The age-specific reference ranges below are still widely used. Each range covers the PSA levels found in 95 percent of healthy men in that age group, so a result above the upper limit is a reason for further discussion with a doctor, not a diagnosis [Oesterling et al., 1993].

• Age 40 to 49: 0.0 to 2.5 ng/mL
• Age 50 to 59: 0.0 to 3.5 ng/mL
• Age 60 to 69: 0.0 to 4.5 ng/mL
• Age 70 to 79: 0.0 to 6.5 ng/mL

These ranges came from a single study population. Ethnicity, family history, prostate size and medicines all affect what a given result means, which is why doctors read a PSA level alongside a man's other risk factors rather than on its own.

PSA Velocity and Other Tests

PSA velocity is the rate at which PSA changes from one test to the next. It was once commonly used to help decide who needed a biopsy, but current American Urological Association (AUA) guidance says PSA velocity should not be used on its own as the reason to order further biomarker tests, imaging or a biopsy [American Urological Association, 2026].

Other blood and urine tests, such as the Prostate Health Index and IsoPSA, can help refine a raised result [National Cancer Institute, 2025]. The AUA guideline says these extra markers may be used when the result would change the decision about whether to biopsy [American Urological Association, 2026].

PSA Levels Are Not a Diagnosis of Cancer

A PSA test cannot tell the difference between cancer and noncancerous conditions. Only a biopsy, in which small samples of prostate tissue are removed and examined under a microscope, can diagnose prostate cancer [National Library of Medicine, 2025]. Only about 25 percent of men who have a biopsy because of a raised PSA are found to have cancer [National Cancer Institute, 2025].

The path from a raised PSA to a biopsy now usually has several steps. The AUA advises repeating a newly raised PSA before moving on to other tests, and PSA is often paired with a digital rectal exam (DRE) [American Urological Association, 2026; National Cancer Institute, 2025]. Doctors may then order a prostate MRI. The AUA guideline says MRI may be used before a first biopsy to improve detection of clinically significant cancer, and should be done before a repeat biopsy if no prostate MRI has been performed. Suspicious areas are scored with the PI-RADS system and can be sampled with a targeted biopsy [American Urological Association, 2026].

If cancer is found, the tissue is graded with the Gleason score and grade group system, which shows how aggressive the cancer is likely to be and helps guide treatment choices.

Benefits and Harms of PSA Screening

A PSA blood test can detect prostate cancer early, but it does not save lives in every case. U.S. Preventive Services Task Force estimates, as summarized by the National Cancer Institute, suggest that for every 1,000 men aged 55 to 69 who are screened over about 13 years, about 1.3 to 2 will avoid death from prostate cancer and about 3 will avoid cancer that spreads. Over the same period, about 240 will have a positive result and about 100 will be diagnosed with prostate cancer [National Cancer Institute, 2025].

Many prostate cancers grow slowly and would never cause health problems. Finding and treating these cancers, known as overdiagnosis and overtreatment, can lead to surgery or radiation that causes lasting side effects such as erectile dysfunction, urinary incontinence or bowel problems [National Library of Medicine, 2025]. False-positive results are also common, affecting about 6 to 7 percent of men in each round of screening, and biopsies can cause pain, bleeding or infection [National Cancer Institute, 2025]. For men found to have low-risk cancer, active surveillance - regular monitoring instead of immediate treatment - is often an option.

Who Should Consider a PSA Test?

Screening recommendations differ between organizations. The U.S. Preventive Services Task Force says that for men aged 55 to 69, PSA screening should be an individual decision made after talking with a clinician about the benefits and harms, and it recommends against PSA screening for men 70 and older. These recommendations were issued in 2018, and the task force is currently updating them [U.S. Preventive Services Task Force, 2018].

The AUA and the Society of Urologic Oncology recommend offering screening every 2 to 4 years to people aged 50 to 69, and say a baseline PSA test may be offered between ages 45 and 50. They advise starting at age 40 to 45 for people at higher risk, including those with Black ancestry, inherited gene mutations or a strong family history of prostate cancer [American Urological Association, 2026]. Prostate cancer is more common in Black men, who also tend to develop it at a younger age and have more serious disease [National Library of Medicine, 2025].

For seniors and men with disabilities, the decision also depends on general health, life expectancy and personal preferences, including whether a man would be well enough to have treatment if cancer were found [National Library of Medicine, 2025]. Medicare covers an annual PSA test for eligible men over age 50 [National Cancer Institute, 2025]. Men over 50, and younger men at higher risk, should talk with a doctor about their own risk of prostate cancer and whether PSA testing is right for them.

Frequently Asked Questions

Do I need to fast before a PSA blood test?

Fasting is not usually needed for a PSA test on its own. If the PSA is being drawn at the same time as other blood work, such as a cholesterol or glucose test, follow the fasting instructions given by your doctor or the lab.

Does a PSA blood test hurt or carry any risks?

A PSA test carries very little risk. You may feel a quick sting when the needle goes in and have slight bruising or soreness at the spot afterward, which usually fades within a day or two.

How long after a prostate biopsy should I wait before having a PSA test?

A prostate biopsy can raise PSA levels for a month or two. Doctors usually wait until this effect has passed before repeating the test so that the result reflects the true baseline level.

What is PSA density?

PSA density is the PSA level divided by the volume of the prostate, which is measured with ultrasound or MRI. It helps doctors judge whether a raised PSA may simply reflect a larger gland, since bigger prostates naturally make more PSA.

Can a digital rectal exam find prostate cancer without a PSA test?

A digital rectal exam lets a doctor feel the back of the prostate for lumps or hard areas, but it cannot reach the whole gland and can miss small tumors. For this reason it is usually used together with a PSA test rather than on its own.

Does an enlarged prostate mean I have prostate cancer?

No. Benign prostatic hyperplasia is a noncancerous enlargement of the prostate that becomes more common with age. It can raise PSA and cause urinary symptoms, but it is a separate condition, although a man can have both BPH and prostate cancer at the same time.

Can PSA results differ between laboratories?

Yes. Different labs may use different testing methods, and results can vary slightly from one method to another. When tracking PSA over time it is best to have the test done at the same lab whenever possible so readings can be compared fairly.

What should PSA levels be after prostate cancer treatment?

After surgery to remove the prostate, PSA usually drops to a very low or undetectable level, and after radiation it falls more slowly. A PSA level that keeps rising over several tests can be the first sign that the cancer has come back, often months or years before any symptoms appear.

References

• American Urological Association. (2026). Early detection of prostate cancer: AUA/SUO guideline (2023, amended 2026).
• National Cancer Institute. (2025). Prostate-specific antigen (PSA) test.
• National Cancer Institute. (2026). Cancer stat facts: Prostate cancer. Surveillance, Epidemiology, and End Results Program.
• National Library of Medicine. (2025). Prostate-specific antigen (PSA) test. MedlinePlus.
• Oesterling, J. E., Jacobsen, S. J., Chute, C. G., Guess, H. A., Girman, C. J., Panser, L. A., and Lieber, M. M. (1993). Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA, 270(7), 860 - 864.
• U.S. Preventive Services Task Force. (2018). Prostate cancer: Screening.

More on this topic: Prostate Cancer Publications, Male Health Publications, Cancer and Tumors Publications, Aging Publications

Insights, Analysis, and Developments

Editorial Note: The PSA test has changed a great deal since it was first treated as a simple pass or fail number. Doctors now repeat a raised result, weigh age and personal risk, and often use MRI before a biopsy, while PSA velocity on its own is no longer considered a good enough reason to biopsy. That shift matters because overdiagnosis is real - many slow-growing cancers would never cause harm, yet treating them can leave men with incontinence or erectile dysfunction, and false-positive results turn up in about 6 to 7 percent of men at each screening round. With a five-year relative survival rate above 98 percent, the goal is no longer to find every prostate cancer but to find the ones that matter, and for older men and men living with disabilities, a frank conversation with a doctor about overall health and personal priorities is as important as the number on the lab report.

Author Credentials: Ian C. Langtree is a writer, editor, and the founder and Editor-in-Chief of Disabled World, which he established in 2004 as one of the longest-running independent resources for disability news and information. Over more than two decades, he has written and edited thousands of articles on disability rights, health, accessibility, and assistive technology. Drawing on a global perspective shaped by extensive travel and lived experience, Ian is a committed advocate of the Social Model of Disability, the framework developed by disabled activists in the 1970s that focuses on removing societal barriers rather than on individual impairments. His writing is grounded in that framework and in a lasting commitment to disability rights, accessibility, and social inclusion. To learn more about Ian's background, expertise, and accomplishments, visit his full biography.